drugset / Trial / NCT00648349

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349

Phase 1 Completed 72 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.

Timeline

Start
2003-05
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg Oral

Indications

No indication recorded.